Lactosaminated-N-succinyl chitosan nanoparticles for hepatocyte-targeted delivery of acyclovir
Source abstract
Abstract
The present study discusses lactose-acyclovir-N-succinyl chitosan nanoparticles (Lac-N-Suc-CSNP) using lactose as an asialoglycoprotein receptor (ASGPR) ligand for hepatic parenchymatic cells targeting. For this purpose, N-succinyl chitosan nanoparticles (N-Suc-CSNP) were prepared previously by ionotropic gelation method and lactose was conjugated to the free amino terminal group of chitosan. Lactose conjugation with N-Suc-CSNP was confirmed by FT-IR and zeta potential measurements. The Lac-N-Suc-CSNP obtained were characterized for their morphology, particle size, polydispersity index, and zeta potential. The Lac-N-Suc-CSNP showed spherical in shape with 220.3 ± 5.0 nm size range, +4.1 ± 0.2 mV zeta potential, 62.5 ± 1.2 % acyclovir entrapment efficiency and showed 27.3 ± 0.9 % cumulative acyclovir release up to 72 h. The acyclovir concentration from Lac-N-Suc-CSNP was found to be 19.9 ± 1.62 μg/g after 24 h administration revealed remarkably targeting potential to the hepatocytes and keep at a high level during the experiment. These results suggest that Lac-N-Suc-CSNP are potentially vector for hepatocytes targeting.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · HIV Research and Treatment · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (24)
Show source-provided references
1. Agrawal P, Gupta U, Jain NK (2007) Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials 28:3349–335910.1016/j.biomaterials.2007.04.004 ↗
2. Bhadra D, Yadav AK, Bhadra S, Jain NK (2005) Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 295:221–23310.1016/j.ijpharm.2005.01.026 ↗
3. Borch RF, Bernstein MD, Durst HD (1971) The cyanohydridoborate anion as a selective reducing agent. J Am Chem Soc 93:2897–290410.1021/ja00741a013 ↗
4. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ (1997) Novel hydrophilic chitosan–polyethylene oxide nanoparticles as protein carrier. J Appl Poly Sci 63:125–13210.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 ↗
5. Griffiths PD (2009) A perspective on antiviral resistance. J Clin Virol 46:3–810.1016/j.jcv.2009.06.017 ↗
6. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J (1999) Significant transport of doxorubicin into the brain with polysorbate 80 coated nanoparticles. Pharm Res 16:1564–156910.1023/A:1018983904537 ↗
7. Jayaseelan S, Suresh S, Sathishkumar G, Sekar V, Perumal P (2010) Bioanalytical method development and validation of lamivudine by RP-HPLC method. Int J Chem Tech Res 2:163–167
8. Kato Y, Onishi H, Machida Y (2000a) Evaluation of N-succinyl-chitosan as a systemic long circulating polymer. Biomaterials 21:1579–158510.1016/S0142-9612(00)00044-2 ↗
9. Kato Y, Onishi H, Machida Y (2000b) Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice. J Control Rel 70:295–30710.1016/S0168-3659(00)00356-4 ↗
10. Kato Y, Onishi H, Machida Y (2003) Application of chitin and chitosan derivatives in the pharmaceutical field. Curr Pharm Biotech 7:303–30910.2174/1389201033489748 ↗
11. Kauper P, Rossi N, Laue C, Schmitt F, Lagopoulos L, Juillerat L, Wandrey C (2007) Chitosan based nanoparticles for medical applications: stability in physiological environments. Eur Cel Mat 13:3–4
12. Kawakami S, Yamashita F, Nishikawa M, Takakura Y, Hashida M (1998) Asialoglycoprotein receptor mediated gene transfer using novel galactosylated cationic liposomes. Biochem Biophys Res Commun 252:78–8310.1006/bbrc.1998.9602 ↗
13. Lin WJ, Chen MH (2006) Synthesis of multifunctional chitosan with galactose as a targeting ligand for glycoprotein receptor. Carbohydr Polym 67:474–48010.1016/j.carbpol.2006.06.017 ↗
14. Mandloi DK, Tyagi PK, Rai VK, Dey S, Ashada RK, Mohanraj P (2009) Method development and validation of RP-HPLC in the application of in vitro dissolution study of lamivudine in bulk drug and tablet formulation. J Chem Pharm Res 1:286–296
15. Mao SJ, Hou SX, He R, Zhang LK, Wei DP, Bi YQ, Jin H (2005) Uptake of albumin nanoparticle surface modified with glycyrrhizin by primary cultured rat hepatocytes. World J Gastroenterol 11:3075–307910.3748/wjg.v11.i20.3075 ↗
16. McMahon BJ, Doo E (2009) The natural history of chronic hepatitis B virus infection. Hepatology 49(5):45–5510.1002/hep.22898 ↗
17. Mourya VK, Inamdar NN (2008) Chitosan-modifications and applications: opportunities galore. React Funct Polym 68(6):1013–105110.1016/j.reactfunctpolym.2008.03.002 ↗
18. Nimje N, Agarwal A, Saraogi GK, Lariya N, Rai G, Agrawal H, Agrawal GP (2009) Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Targ 17(10):777–78710.3109/10611860903115308 ↗
19. Reddy LH, Murthy RSR (2004) Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Pap 148(2):161–16610.5507/bp.2004.029 ↗
20. Song Y, Onishi H, Nagai T (1993) Conjugate of mitomycin C with N-succinyl-chitosan: in vitro drug release properties, toxicity and antitumor activity. Int J Pharm 98:121–13010.1016/0378-5173(93)90048-K ↗
21. Tu J, Zhong S, Li P (2004) Studies on acyclovir dextran conjugate synthesis and pharmacokinetics. Drug Dev Ind Pharm 3:959–96510.1081/DDC-200037232 ↗
22. Utreja S, Jain NK (2001) Advances in controlled and novel drug delivery. CBS Publishers, New Delhi
23. Wu J, Nantz MH, Zern MA (2002) Targeting hepatocytes for drug and gene delivery: emerging novel approach and applications. Frontiers Biosci 7:717–72510.2741/wu2 ↗
24. Zhang ZR, He Q (1999) Study on liver targeting and hepatocytes permeability of acyclovir via polybutylcyanoacrylate nanoparticles. World J Gastroenterol 5(4):330–33310.3748/wjg.v5.i4.330 ↗